EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

STHLM3 NorDCaP : prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance

Nicola Giudici iD, Simone Scuderi, Thorgerdur Palsdottir, Tobias Nordstrom, Martin Eklund, Eva Ferlev Jensby, Michael Borre, Bodil Ginnerup Pedersen, Henrik Grönberg, Karina Dalsgaard Sørensen, Svein R Kjosavik, Anna Lantz

BJU International · 2026-09 · 138 (3) · 471-479

DOI: 10.1111/bju.70366 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 01.07.2026. Verfasst von Nicola Giudici und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting, Prostate. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norwegian Cancer Society, Innovation Fund Denmark & Nordforsk, The Danish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Active surveillance (AS) is the preferred approach for low‐risk prostate cancer (PCa). Recent efforts have explored new biomarkers to reduce the frequency of surveillance biopsy. This study assessed Stockholm3 for predicting PCa upgrading during surveillance biopsies. Materials and Methods The prospective STHLM3‐AS NorDCaP trial included 199 men with International Society of Urological Pathologists grade group 1 (ISUP GG 1) PCa under AS in Sweden, Denmark, and Norway (2019–2022). All men had ISUP GG 1 PCa and received a Stockholm3 test before surveillance biopsies. The primary outcome was ISUP upgrading, defined as ISUP GG 2 or higher.

Results

At surveillance biopsy, 72 of the 199 (36%) men were upgraded. Men with upgraded PCa had higher median Stockholm3 (35; interquartile range [IQR] 26–50) than those without upgrading (23; IQR 14–34, P < 0.01). The area under the receiver operating characteristic curve (AUC) for Stockholm3 was 0.71 (95% confidence interval [CI] 0.64–0.79). For Stockholm3 ≥15, sensitivity, specificity, and negative‐predictive value (NPV) were 0.93 (95% CI 0.85–0.98), 0.26 (95% CI 0.19–0.35), and 0.87 (95% CI 0.72–0.96), respectively, sparing 19% of biopsies while missing five cases (7% of upgrades), none of which were ISUP GG ≥3. At a lower threshold (≥11), sensitivity increased to 0.99 (95% CI 0.93–1.00) with lower specificity (0.11; 95% CI 0.06–0.18) and an NPV of 0.93 (95% CI 0.68–1.00). Prostate‐specific antigen density ≥0.15 showed a sensitivity of 0.60 (95% CI 0.48–0.72), specificity of 0.72 (95% CI 0.63–0.80), and NPV of 0.75 (95% CI 0.66–0.83), with an AUC of 0.71 (95% CI 0.63–0.79). Prostate Imaging‐Reporting and Data System score ≥3 demonstrated a sensitivity of 0.92 (95% CI 0.83–0.97), specificity of 0.33 (95% CI 0.22–0.44), and NPV of 0.84 (95% CI 0.66–0.95), with an AUC of 0.72 (95% CI 0.65–0.79).

Conclusion

In men with low‐risk PCa under AS, Stockholm3 may enhance risk stratification and reduce unnecessary biopsies. Prostate‐specific antigen density and multiparametric magnetic resonance imaging showed comparable performance, with Stockholm3 providing a potentially practical blood‐based complement in a multimodal strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsWatchful WaitingProstateHumansMaleProspective StudiesAgedMiddle AgedSwedenNeoplasm GradingBiopsyDenmarkProstate-Specific AntigenNorway

Stichwörter der Autor:innen

Stockholm3active surveillanceprostate cancerrisk stratificationsurveillance biopsies

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Urology, University Hospital Bern, Bern, Switzerland.
  • Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Nicola Giudici

Förderung

  • Norwegian Cancer Society
  • Innovation Fund Denmark & Nordforsk
  • The Danish Cancer Society
  • Kreftforeningen
  • Kræftens Bekæmpelse

Zitieren

APA

Giudici, N., Scuderi, S., Palsdottir, T., Nordstrom, T., Eklund, M., Jensby, E. F., Borre, M., Pedersen, B. G., Grönberg, H., Sørensen, K. D., Kjosavik, S. R., & Lantz, A. (2026). STHLM3 NorDCaP : prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance. BJU International, 138(3), 471-479. https://doi.org/10.1111/bju.70366

Vancouver

Giudici N, Scuderi S, Palsdottir T, Nordstrom T, Eklund M, Jensby EF, et al. STHLM3 NorDCaP : prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance. BJU International. 2026;138(3):471-479. doi:10.1111/bju.70366

BibTeX
@article{Giudici2026,
  author = {Giudici, Nicola and Scuderi, Simone and Palsdottir, Thorgerdur and Nordstrom, Tobias and Eklund, Martin and Jensby, Eva Ferlev and Borre, Michael and Pedersen, Bodil Ginnerup and Grönberg, Henrik and Sørensen, Karina Dalsgaard and Kjosavik, Svein R and Lantz, Anna},
  title = {STHLM3 NorDCaP : prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance},
  journal = {BJU International},
  year = {2026},
  volume = {138},
  number = {3},
  pages = {471--479},
  doi = {10.1111/bju.70366}
}
Kostenlos starten →